title: [Exploratory analysis of the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma].
abstract: OBJECTIVE
  To explore the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma (RCC) .
  
  
  METHODS
  A total of 136 patients with advanced RCC were treated with sunitinib from 2008 to 2011. There were 91 males and 45 females with an average age of 56 years. Their 6-week therapy cycle was 4 weeks of sunitinib 50 mg daily followed by 2-week off-treatment (schedule 4/2). The median follow-up time was 15 months. Correlation between toxicities and overall survival (OS) was evaluated in a Cox model using log-transformed levels after adjusting for MSKCC model.Log-rank test and Cox proportional hazard model were used to assess the value of drug toxicity as the prognostic factors.
  
  
  RESULTS
  The increased hemoglobin on cycle 1 day 14 (HR:0.950, 95%CI:0.923-0.978) and the increased lymphocytes on cycle 1 days 28 and 42 (HR:0.405, 95%CI:0.203-0.809, HR:0.394, 95%CI:0.179-0.867) were significantly associated with OS (P adj = 0.001, 0.014 and 0.022 respectively). Hypertension class III/IV (HR:0.066, 95%CI:0.008-0.582), and the number of neutrophils screening and lymphocyte count ratio (HR:2.537, 95%CI:1.182-5.404) were the survival prognosis independent predictors.
  
  
  CONCLUSIONS
  Early hematopoietic toxicities may potentially predict the outcomes of advanced RCC after a therapy of sunitinib.
authors.affiliation: Department of Urology, Fudan University Cancer Hospital, Shanghai 200032, China.
authors.forename: Ya-ping
authors.initials: YP
authors.lastname: Hong
authors.affiliation: Department of Urology, No.10 People's Hospital of Tongji University, Shanghai 200072, China.
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Yao
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Email: dwyeli@163.com.
authors.forename: Ding-wei
authors.initials: DW
authors.lastname: Ye
authors.forename: Guo-hai
authors.initials: GH
authors.lastname: Shi
authors.forename: Shi-lin
authors.initials: SL
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.forename: Hai-liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Yi-jun
authors.initials: YJ
authors.lastname: Shen
authors.forename: Yi-ping
authors.initials: YP
authors.lastname: Zhu
authors.forename: Chun-guang
authors.initials: CG
authors.lastname: Ma
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Xiao
authors.forename: Xiao-jian
authors.initials: XJ
authors.lastname: Qin
authors.forename: Guo-wen
authors.initials: GW
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib